InvestorsHub Logo
Followers 1
Posts 62
Boards Moderated 0
Alias Born 10/13/2017

Re: None

Thursday, 10/21/2021 6:13:36 PM

Thursday, October 21, 2021 6:13:36 PM

Post# of 6316
Skye recently updated its clinical development strategy and timeline for its Phase I study, focused on safety and tolerability in 48 healthy volunteers, which is being initiated in Q2-22 in Australia.

I'll believe it when I see it. I've seen this data when they were NMUS, then when they were EMBI, now SKYE has managed to regurgitate the same useless press release. This isn't some new company this is same bag of crap it was 3 names ago. Another Dhillon dumpster fire...outstanding
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SKYE News